Pharma Business - April 16, 2020
Rybelsus approved for the treatment of adults with type 2 diabetes in the EU
Novo Nordisk has announced that the European Commission (EC) has granted marketing authorization for Rybelsus (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. The marketing authorization applies to all 27 European Union member states and the United Kingdom. Based […]
Clinical Trials - April 16, 2020
Novo Nordisk’s Saxenda shows promising results
Novo Nordisk has announced that a peer-reviewed journal published the results of a phase 3 trial evaluating the investigational use of Saxenda in adolescents with obesity. The study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting in San Francisco, US, and will be published in a supplemental issue of the Journal […]
Clinical Trials - April 7, 2020
Novo Nordisk pauses trials in haemophilia A and B
Novo Nordisk has announced that two clinical trials in the concizumab phase 3 programme (explorer7 and 8) and one clinical trial in the phase 2 programme (explorer5) have been paused. The three clinical trials were investigating concizumab prophylaxis treatment in haemophilia A and B patients regardless of inhibitor status. Consequently, no additional patients will be […]
Pharma Business - February 11, 2020
Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities
Novo Nordisk has announced plans to invest DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark. The facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes […]
Pharma Business - January 16, 2020
Novo Nordisk’s Ozempic approved in the US for CV risk reduction in people with type 2 diabetes and established CVD
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a label expansion based on a supplemental New Drug Application (sNDA) for Ozempic (once-weekly semaglutide) for the indication of reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type […]
Collaboration - November 27, 2019
Novo Nordisk and UNICEF announce new partnership
Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean. Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight […]
